Published in Neoplasia on August 08, 2001
Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci U S A (2002) 1.93
18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med (2009) 1.52
Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer. Dig Dis Sci (2006) 1.18
Assessment of quantitative FDG PET data in primary colorectal tumours: which parameters are important with respect to tumour detection? Eur J Nucl Med Mol Imaging (2007) 1.15
Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging (2004) 1.01
Single group study to evaluate the feasibility and complications of radiofrequency ablation and usefulness of post treatment position emission tomography in lung tumours. World J Surg Oncol (2004) 0.88
FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA. World J Surg Oncol (2007) 0.88
Biological factors, tumor growth kinetics, and survival after metastasectomy for pulmonary melanoma. Ann Surg Oncol (2009) 0.84
Early treatment response monitoring using 2-deoxy-2-[ 18F]fluoro-D-glucose positron emission tomography imaging during fractionated radiotherapy of head neck cancer xenografts. Biomed Res Int (2014) 0.84
Nucleocytoplasmic shuttling of hexokinase II in a cancer cell. Biochem Biophys Res Commun (2010) 0.82
Prognostic value of 18-fluorodeoxyglucose positron emission tomography-computed tomography in resectable colorectal cancer. World J Gastroenterol (2012) 0.81
Elevated tumor-to-liver uptake ratio (TLR) from (18)F-FDG-PET/CT predicts poor prognosis in stage IIA colorectal cancer following curative resection. Eur J Nucl Med Mol Imaging (2017) 0.78
Hacking hexokinase halts tumor growth. Cancer Biol Ther (2008) 0.77
Single Cell "Glucose Nanosensor" Verifies Elevated Glucose Levels in Individual Cancer Cells. Nano Lett (2016) 0.77
Initial Staging of Locally Advanced Rectal Cancer and Regional Lymph Nodes: Comparison of Diffusion-Weighted MRI With 18F-FDG-PET/CT. Clin Nucl Med (2016) 0.75
Evaluation of repeated [(18)F]EF5 PET/CT scans and tumor growth rate in experimental head and neck carcinomas. EJNMMI Res (2014) 0.75
Gamma probes and their use in tumor detection in colorectal cancer. Int Semin Surg Oncol (2008) 0.75
Relationship Between Dual-Time Point FDG PET and Immunohistochemical Parameters in Preoperative Colorectal Cancer: Preliminary Study. Nucl Med Mol Imaging (2012) 0.75
Expression of Glut-1 and HK-II in Pancreatic Cancer and Their Impact on Prognosis and FDG Accumulation. Transl Oncol (2016) 0.75
Targeting energy metabolism of cancer cells: Combined administration of NCL-240 and 2-DG. Int J Pharm (2017) 0.75
(18)F-FDG-PET/CT in Initiation and Progression of Inflammation and Infection. Mol Imaging Radionucl Ther (2017) 0.75
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
On the origin of cancer cells. Science (1956) 49.55
Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem (1981) 38.93
Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer (1997) 2.81
Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med (1992) 2.30
Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res (2000) 2.13
Performance characteristics of a whole-body PET scanner. J Nucl Med (1994) 2.08
Enzymology of cancer cells (second of two parts). N Engl J Med (1977) 2.00
Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer (1997) 1.97
(F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res (2000) 1.89
Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res (1996) 1.84
Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology (1991) 1.80
Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol (2000) 1.69
Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J (1999) 1.64
The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg (1996) 1.64
Glucose-6-phosphatase activity in normal, pre-cancerous, and neoplastic tissues. Cancer Res (1955) 1.59
Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med (1997) 1.58
Growth factors rapidly induce expression of the glucose transporter gene. J Biol Chem (1988) 1.53
GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res (1996) 1.42
Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med (1999) 1.41
Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg (1999) 1.41
Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer (1998) 1.41
Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res (1999) 1.31
COMPARATIVE BIOCHEMISTRY OF HEPATOMAS. III. CARBOHYDRATE ENZYMES IN LIVER TUMORS OF DIFFERENT GROWTH RATES. Cancer Res (1963) 1.30
Glucose catabolism in cancer cells: amplification of the gene encoding type II hexokinase. Cancer Res (1996) 1.29
Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med (1998) 1.25
Glucose catabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase. J Biol Chem (1995) 1.24
Regulation of glucose-transporter gene expression in vitro and in vivo. Diabetes Care (1990) 1.24
Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med (1992) 1.22
Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg (1996) 1.19
High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev (1995) 1.16
Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. J Nucl Med (1996) 1.15
Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med (1998) 1.13
FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol (1994) 1.11
Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med (1988) 1.08
Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer (1988) 1.07
FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med (1998) 1.07
Differences in expression and intracellular distribution of hexokinase isoenzymes in rat liver cells of different transformation stages. Biochim Biophys Acta (1994) 1.07
Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg (1994) 1.05
Purification and characterization of a bindable form of mitochondrial bound hexokinase from the highly glycolytic AS-30D rat hepatoma cell line. Cancer Res (1988) 1.03
Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology (1987) 1.03
Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia (2000) 1.01
Complete amino acid sequence of the type II isozyme of rat hexokinase, deduced from the cloned cDNA: comparison with a hexokinase from novikoff ascites tumor. Arch Biochem Biophys (1991) 0.98
The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxyglucose retention in murine tumor models. Nucl Med Biol (1996) 0.97
Colon carcinoma cells switch their response to transforming growth factor beta 1 with tumor progression. Cell Growth Differ (1994) 0.97
COMPARATIVE BIOCHEMISTRY HEPATOMAS. IV. ISOTOPE STUDIES OF GLUCOSE AND FRUCTOSE METABOLISM IN LIVER TUMORS OF DIFFERENT GROWTH RATES. Cancer Res (1963) 0.95
Mechanisms related to [18F]fluorodeoxyglucose uptake of human colon cancers transplanted in nude mice. J Nucl Med (1999) 0.95
Hexokinase, differentiation and growth rates of transplanted rat tumors. Cancer Res (1970) 0.91
Recurrent rectal cancer and scar: differentiation with PET and MR imaging. Radiology (1992) 0.89
Hexokinase isozyme patterns of human uterine tumors. Cancer (1972) 0.85
Changes in FDG Tumor Uptake during and after Fractionated Radiation Therapy in a Rodent Tumor Xenograft. Clin Positron Imaging (1999) 0.84
PET-study of intracranial meningiomas: correlation with histopathology, cellularity and proliferation rate. Acta Neurochir Suppl (1996) 0.84
FDG-PET evaluation of retroperitoneal metastases of testicular cancer before and after chemotherapy. J Nucl Med (1997) 0.77
Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature (1988) 13.42
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med (1999) 7.04
Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg (2001) 5.94
Radiometric detection of the metabolic activity of Mycobacterium tuberculosis. J Nucl Med (1975) 5.30
Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet (1987) 4.18
Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med (1988) 4.02
Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet (1988) 3.30
Automated detection of Haemophilus influenzae. Appl Microbiol (1973) 3.16
Segment-oriented hepatic resection in the management of malignant neoplasms of the liver. J Am Coll Surg (1998) 3.04
Perioperative outcomes of major hepatic resections under low central venous pressure anesthesia: blood loss, blood transfusion, and the risk of postoperative renal dysfunction. J Am Coll Surg (1998) 2.97
Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer (1997) 2.81
Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg (1998) 2.81
Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg (2000) 2.60
Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg (2001) 2.57
Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. Arch Surg (1999) 2.57
Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res (1998) 2.55
Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol (2000) 2.48
A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res (1998) 2.43
Long-term results after resection for gallbladder cancer. Implications for staging and management. Ann Surg (1996) 2.39
Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol (1999) 2.38
Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst (1991) 2.19
Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol (2008) 2.12
Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol (2001) 2.06
One hundred consecutive hepatic resections. Blood loss, transfusion, and operative technique. Arch Surg (1994) 2.03
Imaging transgene expression with radionuclide imaging technologies. Neoplasia (2000) 2.03
Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol (1989) 2.00
Management of 155 patients with benign liver tumours. Br J Surg (2001) 1.97
Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol (2002) 1.96
Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med (1999) 1.95
[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab (1999) 1.90
Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal liver metastases. J Gastrointest Surg (2000) 1.85
Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models. FASEB J (1989) 1.82
Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol (1999) 1.75
Results of hepatic resection for sarcoma metastatic to liver. Ann Surg (2001) 1.75
Bone metastases from thyroid carcinoma: a histopathologic study with clinical correlates. Arch Pathol Lab Med (2000) 1.74
Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys (2004) 1.74
Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol (1993) 1.73
Extended hepatic resection: a 6-year retrospective study of risk factors for perioperative mortality. J Am Coll Surg (2001) 1.69
Quantitative imaging of iodine-124 with PET. J Nucl Med (1996) 1.69
Hepatic resection for noncolorectal, nonneuroendocrine metastases: a fifteen-year experience with ninety-six patients. Surgery (1997) 1.68
Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med (1998) 1.67
Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J (1999) 1.64
Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. J Clin Oncol (2003) 1.63
Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid (2000) 1.59
Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/cyclin T1 heterodimer responsible for P-TEFb-mediated tat stimulation of HIV-1 transcription. J Biol Chem (2000) 1.59
Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab (2000) 1.59
A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases. Cancer (2001) 1.57
A prospective analysis of staging laparoscopy in patients with primary and secondary hepatobiliary malignancies. J Gastrointest Surg (2000) 1.57
Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol (1998) 1.56
Phase and amplitude binning for 4D-CT imaging. Phys Med Biol (2007) 1.52
Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. Surg Gynecol Obstet (1990) 1.50
Radiopharmacology of a simplifield technetium-99m-colloid preparation for photoscanning. J Nucl Med (1966) 1.49
FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med (2001) 1.49
Effect of respiratory gating on reducing lung motion artifacts in PET imaging of lung cancer. Med Phys (2002) 1.48
In vitro complex formation and biodistribution of mouse antitumor monoclonal antibody in cancer patients. J Nucl Med (1989) 1.43
Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest (1983) 1.42
Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol (1988) 1.41
Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol (1994) 1.41
Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg (1999) 1.41
Triumph over mischance: a role for nuclear medicine in gene therapy. J Nucl Med (1997) 1.41
In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. J Nucl Med (1990) 1.41
Surgical options in the treatment of hepatic metastasis from colorectal cancer. Curr Probl Surg (1995) 1.40
Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. Radiology (2001) 1.40
Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol (2009) 1.39
Quantitative bone metastases analysis based on image segmentation. J Nucl Med (1997) 1.36
Quantitation of respiratory motion during 4D-PET/CT acquisition. Med Phys (2004) 1.35
Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol (1993) 1.35
Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep (1984) 1.35
3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. Int J Oncol (1998) 1.35
Dimensions of the normal adult spleen scan and prediction of spleen weight. J Nucl Med (1971) 1.33
The Caenorhabditis elegans maternal-effect sterile proteins, MES-2, MES-3, and MES-6, are associated in a complex in embryos. Proc Natl Acad Sci U S A (2001) 1.32
Cholangiocarcinoma at the hepatic hilus: sonographic findings. AJR Am J Roentgenol (1997) 1.32
Partial hepatectomy accelerates local tumor growth: potential roles of local cytokine activation. Surgery (1998) 1.32
Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med (1986) 1.27
Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg (1985) 1.27
Peripheral blood leukocyte kinetics following in vivo lipopolysaccharide (LPS) administration to normal human subjects. Influence of elicited hormones and cytokines. Ann Surg (1989) 1.27
Midazolam changes cerebral blood flow in discrete brain regions: an H2(15)O positron emission tomography study. Anesthesiology (1997) 1.25
A general approach to the non-invasive imaging of transgenes using cis-linked herpes simplex virus thymidine kinase. Neoplasia (1999) 1.25
Imaging of melanoma with L-131-labeled monoclonal antibodies. J Nucl Med (1983) 1.24
Effects of obstetrician gender on communication and patient satisfaction. Obstet Gynecol (1999) 1.23
Use-dependent structural events in recovery of function. Adv Neurol (1997) 1.23
Minimally invasive localization of oncolytic herpes simplex viral therapy of metastatic pleural cancer. Cancer Gene Ther (2006) 1.23
Prevention of hepatic tumor metastases in rats with herpes viral vaccines and gamma-interferon. J Clin Invest (1997) 1.22
Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endocrinol Metab (2013) 1.21
Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol (1996) 1.21
What is the yield of intraoperative ultrasonography during partial hepatectomy for malignant disease? J Am Coll Surg (2001) 1.21
Complete resection of the caudate lobe of the liver: technique and results. Br J Surg (1996) 1.21
Rates and patterns of recurrence for percutaneous radiofrequency ablation and open wedge resection for solitary colorectal liver metastasis. J Gastrointest Surg (2007) 1.19
Isolated hepatic splenosis: first reported case. HPB Surg (1998) 1.18
The radionuclide ejection fraction: a comparison of three radionuclide techniques with contrast angiography. J Nucl Med (1977) 1.18
Liver resection for metastatic colorectal cancer: assessing the risk of occult irresectable disease. J Am Coll Surg (1999) 1.18